| Literature DB >> 24515752 |
Valentina Bollati1, Laura Angelici, Giovanna Rizzo, Laura Pergoli, Federica Rota, Mirjam Hoxha, Francesco Nordio, Matteo Bonzini, Letizia Tarantini, Laura Cantone, Angela C Pesatori, Pietro Apostoli, Andrea A Baccarelli, Pier Alberto Bertazzi.
Abstract
Cardiovascular disease risk has been consistently linked with particulate matter (PM) exposure. Cell-derived microvesicles (MVs) are released into plasma and transfer microRNAs (miRNAs) between tissues. MVs can be produced by the respiratory system in response to proinflammatory triggers, enter the circulatory system and remotely modify gene expression in cardiovascular tissues. However, whether PM affects MV signaling has never been investigated. In this study, we evaluated expression of microRNAs contained within plasma MVs upon PM exposure both in vivo and in vitro. In the in vivo study, we isolated plasma MVs from healthy steel plant workers before and after workplace PM exposure. We measured the expression of 88 MV-associated miRNAs by real-time polymerase chain reaction. To assess a possible source of the MV miRNAs identified in vivo, we measured their miRNA expression in PM-treated A549 pulmonary cell lines in vitro. MiRNA profiling of plasma MVs showed 5.62- and 13.95-fold increased expression of miR-128 and miR-302c, respectively, after 3 days of workplace PM exposure (P < 0.001). According to Ingenuity Pathway Analysis, miR-128 is part of coronary artery disease pathways, and miR-302c is part of coronary artery disease, cardiac hypertrophy and heart failure pathways. In vitro experiments confirmed a dose-dependent expression of miR-128 in MVs released from A549 cells after 6 h of PM treatment (P = 0.030). MiR-302c was expressed neither from A549 cells nor in reference lung RNA. These results suggest novel PM-activated molecular mechanisms that may mediate the effects of air pollution and could lead to the identification of new diagnostic and therapeutic interventions.Entities:
Keywords: A549 cells; Particulate matter; microRNAs; microvesicles; steel plant workers
Mesh:
Substances:
Year: 2014 PMID: 24515752 PMCID: PMC4125569 DOI: 10.1002/jat.2987
Source DB: PubMed Journal: J Appl Toxicol ISSN: 0260-437X Impact factor: 3.446
MicroRNAs with significant differential expression between baseline and postexposure samples
| MicroRNA | Mature sequence | Fold change | False discovery rate | |
|---|---|---|---|---|
| hsa-miR-302c | UAAGUGCUUCCAUGUUUCAGUG | 13.95 | < 0.001 | 0.06 |
| hsa-miR-128 | UCACAGUGAACCGGUCUCUU | 5.62 | < 0.001 | 0.05 |
| hsa-miR-28-3p | CACUAGAUUGUGAGCUCCUGG | 3.64 | 0.01 | 0.30 |
| hsa-miR-125a-5p | UCCCUGAGACCCUUUAACCUGUG | 2.98 | 0.04 | 0.54 |
| hsa-let-7 g | UGAGGUAGUAGUUUGUACAGU | 2.27 | 0.02 | 0.37 |
| hsa-miR-181a | AACAUUCAACGCUGUCGGUGAG | 1.72 | 0.02 | 0.37 |
Figure 1Volcano plot representing differential microRNA expression in plasma microvesicles of steel plant workers pre- and postexposure.
Top five networks, functions and molecules associated with miR-302c and miR-128 targets identified by Ingenuity Pathway Analysis software analysis
| Network | Top functions | Score | Focus molecules | Molecules in network |
|---|---|---|---|---|
| hsa-miR-128 | ||||
| 1 | Connective tissue development and function, connective tissue disorders, developmental disorder | 44 | 31 | BCR, C11orf41, C17orf70, CLIC4, CSDC2, CYP4F2, DAZAP2, DLGAP3, FANCA, Fgf, FUBP3, GNS, GRB2, LASP1, LPCAT1, MAP2K1/2, NAP1L5, NEDD4, NKX3-2, PAX9, PIK3R1, ProSAPiP1, RBM33, REPS1, Sapk, SCAMP3, SHANK3, SMAD5, SMAP1, SMURF2, SOX7, SPRY2, SPTBN1, WIPF2, ZNF24 |
| 2 | Organ development, respiratory system development and function, skeletal and muscular system development and function | 44 | 31 | AFF4, AK2, C5orf13, C7orf42, CDC14B, CTDSP2, CTDSPL, EYA4, FAM177A1, FOXP2, FOXP4, FRYL, GNG12, Ige, INO80D, MAN2A1, MAPK14, MED13, MED14, Mediator, Mek, MET, MIR124 (human), NAA15, NAA50, NIPBL, PDPN, PTPN3, RAI14, RUVBL2, SASH1, SNAI1, TLK2, YWHAB, ZCCHC24 |
| 3 | Post-translational modification, protein degradation, protein synthesis | 39 | 29 | ANK1, ARRDC4, DTX1, DTX3L, E2F7, EDAR, GFPT2, Ikk (family), ITCH, KLF3, LIN28A, Mapk kinase, MARCH5, MFHAS1, MIR125B (human), N4BP1, NF-κB (complex), NFX1, PELI3, PPARα-RXRα, RNF182, RNF144A, SNX18, TAB3, TBC1D1, TMOD2, TRIM23, TRIM32, TXNIP, UBA6, UBE2, UBE2E2, UBE2N, UBE2V1, WTAP |
| 4 | Connective tissue disorders, developmental disorder, skeletal and muscular disorders | 39 | 29 | ATXN10, CCDC71, CCM2, CNOT6, FADS1, FBLN2, Gsk3, H3F3A/H3F3B, HAND2, HCN4, HDAC4, HDAC5, HIC1, Histone h3, Histone h4, HOXA10, HOXA13, HOXB3, ING5, IRF4, MEIS2, MIR1, MMD, MYST2, NAV2, NFAT (complex), Notch, NOVA1, PCM1, PHF15, PHGDH, POM121/POM121C, RERE, SIRT1, SLC7A11 |
| 5 | Gene expression, cardiac output, cardiovascular system development and function | 38 | 29 | 26 s Proteasome, ARHGAP21, Caspase, CPD, Cytochrome c, DUSP5, FSH, GCC2, GIGYF2, INSR, KIAA1033, KIAA1109, KITLG, MEPCE, MN1, MNT, NCAM1, NEK1, NRP2, OPA1, PDHX, PLXND1, POGZ, PP2A, PRDM16, RUNX1, SERTAD2, SMAD2, SP1, SP4, SRP72, TNRC6B, UBE2NL, Vegf, ZNHIT6 |
| hsa-miR-302c | ||||
| 1 | Dermatological diseases and conditions, infectious disease, developmental disorder | 43 | 31 | Ahr-aryl hydrocarbon-Arnt, ALDH1B1, BCL11A, BCL11B, CC2D1A, E2F7, EDAR, GABPB1, Ikk (family), IL1F9, IRAK4, KLF3, LMO3, MICA, NCOA7, NF-κB (complex), NHLH2, NR2F2, PELI1, RNF216, RORA, TAX1BP1, TPMT, TRAFD1, TRIM8, TRIM36, TRIP11, UBE2, UBE2B, UBE2G1, UBE2H, UBE2J1, UBE2R2, UBE2V1, ZFPM2 |
| 2 | Cell morphology, cellular function and maintenance, connective tissue development and function | 43 | 31 | ADD3, ANK2, BRCC3, CRTC2, DCAF7, DCTN4, DUSP2, Dynein, DYRK2, ERK1/2, FAM175B, KIF3B, KLF13, MARCH5, MARK1, MARK3, MFN2, MIB1, MTUS1, Na+,K + -ATPase, NEFL, NTN4, Rab5, RAB5C, RABEP1, RAPGEF2, RB1CC1, SCN2A, SHC4, SIK1, TRIM2, UBE2W, ULK1, WDR26, WDR76 |
| 3 | Digestive system development and function, gene expression, embryonic development | 37 | 28 | ACVR1C, ALX4, ARL4D, BAMBI, CCDC25, CDC40, DAZAP2, DCUN1D1, FOXP1, GATAD2B, Groucho, LEF1, Lefty, LEFTY1, LEFTY2, Mapk, MNT, MXD1, NFYA, PALLD, PRDM16, PRRX1, PURB, RGMA, RUNX3, Smad, SMAD2, Smad1/5/8, Smad2/3, TGFBR, TGFBR2, TLE4, TNRC6B, TPD52L1, TPD52L3 |
| 4 | Cell cycle, gene expression, molecular transport | 35 | 27 | 20s proteasome, 26 s Proteasome, BNIP3L, CCND1, CDCA7, CUL3, DIP2B, DMTF1, FAM40B, FOXO3, HMGCS2, Ikb, IKK (complex), IRF, MAP3K14, MHC CLASS I (family), NCOA3, NfkB1-RelA, ORC4, POC5, POLK, POLQ, RAD18, RAD23B, SIKE1, SLC40A1, SPOP, SQSTM1, STEAP3, TAPT1, TP53INP2, UBE3A, Ubiquitin, XIAP, ZRANB1 |
| 5 | Tissue morphology, behavior, nervous system development and function | 33 | 28 | ABCG2, APP, ATF6B, BCL2L11, CALML4, COL11A1, cytochrome |
Figure 2Growth profile of A549 cells treated with increasing doses of PM10.
Figure 3miR-128 expression in microvesicles purified from culture media of A549 cells treated with increasing doses of PM10 at different times.
Figure 4Possible roles of plasma microvesicle microRNAs in mediating cardiovascular effects of particular matter.